{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-25-000149","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.861930+00:00","generated_at":"2026-05-17T17:59:05.743721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pliant Therapeutics discontinues bexotegrast in IPF; Q2 net loss narrows to $43.3M","bullets":["Bexotegrast development in IPF stopped due to unfavorable risk-benefit; full BEACON-IPF data to be published.","Phase 1 trial of PLN-101095 in solid tumors ongoing; data from top two dose cohorts expected by end of 2025.","Workforce restructuring largely complete; cash, cash equivalents and short-term investments at $264.4M as of June 30.","Q2 R&D expenses fell to $32.2M from $45.6M; G&A dropped to $13.4M from $15.0M.","Net loss of $43.3M improved from $55.9M in prior-year quarter, driven by restructuring and trial discontinuation."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-25-000149","json":"https://secwatch.observer/filing/0001746473-25-000149.json","markdown":"https://secwatch.observer/filing/0001746473-25-000149.md","text":"https://secwatch.observer/filing/0001746473-25-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000149/0001746473-25-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000149/plrx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:59:05.743721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}